Overview. Amway’s 2Q22 revenue declined marginally by 0.4% YoY mostly dragged by lower demand from home appliances despite an increase in buyer base for health & wellness and personal care categories as well as selling price hikes. Nevertheless, net profit jumped 90.7% YoY with margin soaring to 4.2% (+2 ppts YoY) thanks to normalizing costs that associated with Amway Business Owner (ABO) incentives and awards.
Key highlights. On QoQ basis, net profit dropped by 25.7% mainly attributed to lower sales from i) higher pre-price increase buy-up in previous quarter and ii) timing difference in sales and marketing events. Going forward we expect Amway to experience a softening in demand for its premium products given inflationary environment and prolong weakness in Ringgit which may make its products more expensive.
Against estimates: Above. 1H22’s net profit of RM35.2mn was above our and consensus forecast, accounting 74% and 64% of full year forecast respectively. The main deviation against our forecast was due to lower-than-expected operating costs that associated with ABO expenses.
Dividend. Declared a second interim DPS of 5 sen, bringing YTD DPS to 10 sen (1H21: 10 sen). We estimate a total DPS of 29 sen for FY22, translating into a dividend yield of 5.8%.
Outlook. Amway’s outlook remains challenging given inflationary risk that could dampen consumer spending ability, a bane particularly for premium products. The prolong weakness of Ringgit against the USD could also put margins under pressure as the majority of Amway products are imported from the US.
Earning revision. We revised higher our FY22F/F23F earnings by 23%/25% after factoring higher margin due to the normalization of ABO incentives and rewards expenses.
Our call. Maintain a HOLD call recommendation with a higher DDM-derived TP of RM5.20 (from RM4.80) based on WACC of 8.3% and TG of 1%. This implies 15x FY23F PE (close to Amway’s -1.5SD 5-years average forward PE). We believe this is fair considering the inflationary pressures and potential lower sales volume due to premium prices.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....